DISCOVERY
Piramal Discovery Solutions offers a comprehensive range of Contract Research Services from our state-of-the-art research centre in India to support drug discovery activities
Synthetic Chemistry
Piramal has been offering from mg to gm scale discovery chemistries to its customers from North America, Europe and Asia
In-vitro-Biology Services
Piramal’s in vitro Biology is designed to provide best in class support to our clients to enable their preclinical drug discovery.
In-vitro-ADME Services
Piramal's in-vitro labs provide ADME services for faster and improved decision making for our Chemistry clients
Route Scouting
Assisting our partners in discovering and developing efficient and cost effective routes
Non-GMP Kilo lab
Piramal’s fully-equipped kilo-lab allows for rapid development of scalable and robust chemical processes using advanced process methodologies
Analytical Support Services
The chemists at Piramal are supported by a specialist & fully dedicated analytical team which operates 24/7 with suites containing advanced analytical equipment

A sneak peek into our facility

DEVELOPMENT
Piramal offers clinical development services from Phase I to Phase III for various dosage form such as Oral solids, liquids, creams, ointments, and sterile injectable
Process R&D services
Process development for small molecule intermediates, APIs and HPAPIs
Pre-Formulation Studies
Expert approach ensures quality of drugs from discovery to commercial supply
Pharmaceutical Drug Development Services
Pharmaceutical Development of oral solids, liquids, creams, ointments, and sterile injectable.
Analytical Support Services
Range of services, including method development, stability studies, validation and transfer
Regulatory Services
Expert clinical & regulatory support across all phases of drug development programs
Clinical Trial Services
Clinical Trial Manufacturing, Packaging and Supply Services using our global network

A sneak peek into our facility

MANUFACTURING
Piramal offers contract manufacturing for API, HPAPI and a wide variety of dosage forms. Our global manufacturing sites located across North America, Europe and India offer the highest standards of quality and service to the customers
API Manufacturing
We provide the manufacture and supply of Active Pharmaceutical Ingredients (APIs) on an integrated manufacturing model across North America, Europe and Asia
HPAPI
Piramal Pharma Solutions offers the development and manufacturing of High Potency API services from its Riverview facility
Finished Dosage Manufacturing
Lifecycle Management
With very small quantities of active pharmaceutical ingredients (API) or drug-able candidate molecules

A sneak peek into our facility

ANTIBODY DRUG CONJUGATION
Piramal is the global leader in delivering customer-centric solutions in the field of Antibody Drug Conjugates (ADCs) and other bioconjugates to global biopharmaceutical companies
Proof-Of-Concept Studies
Piramal offers a fast-track early stage development service for your ADC programmes. Whether you are selecting your candidate mAb, linker or toxin
Process Development and Scale Up
Piramal offers ADC process development and scale-up through Tox manufacture and into GMP manufacture
ADC Manufacturing
World-leading multi-product facility for clinical and commercial manufacturing of antibody drug conjugates (ADCs)
ADC Fill/Finish
Piramal offers aseptic filling of ADC drug product through our FDA-inspected state-of- the-art manufacturing facility in Lexington, KY
Analytical Development Services
Analytical development team covers a wide range of analytical methods from small molecule analysis through to cell killing assays and ELISA development

A sneak peek into our facility

GENERIC APIs
Piramal’s Generic API division offers an indigenous basket of off-patent APIs for global markets. With the declining pipeline of new drugs in the pharmaceutical industry, our customers are looking for off-patent APIs with competitive cost and quality
Mumbai, India
We have an experienced team of over 28 scientists including 8 Ph.D.’s dedicated to innovation in new product development, cost optimization, and novel route scouting projects
Generic API Products

A sneak peek into our facility

  • 2020s
  • 2010s
  • 2000s
  • 1990s
  • 1980s

2021

• Piramal Pharma Solutions acquires minority stake in Yapan Bio, India-Based CDMO providing expertise in Biologics and Vaccines.

Piramal 2021
19
18
Piramal 2021

2021

• Piramal Pharma Solutions completes acquisition of Hemmo Pharmaceuticals, a Leading Indian Manufacturer of Peptide APIs.

2020

• Piramal Pharma Solutions completes acquisition of Solid Oral Dosage Drug Product Facility in Sellersville, Pennsylvania from G&W Laboratories Inc

Piramal 2020
17
16
Piramal 2016

2016

• Piramal acquires Ash Stevens Inc., a US-based contract developer and manufacture of drugs specializing in high potent APIs

2015

• Piramal acquires Kentucky-based speciality pharmaceutical CDMO, Coldstream Laboratories Inc.

Piramal 2015
15
14
Piramal 2012

2012

• Piramal Healthcare Limited is renamed to Piramal Pharma Limited.

2011

  • Fortune 500 ranks Piramal Healthcare in the top-50 largest corporations across India
  • UN Conference on the Trade and Development’s World Investment Report 2011 ranks Piramal Healthcare as No.5 in the top 10 pharmaceutical contract manufactures worldwide
  • Piramal acquires Oxygen Bio-research, a CRO based in Ahmedabad, India that offers medicinal chemistry services
Piramal 2011
13
12
Piramal 2010

2010

• Piramal sells the diagnostics division to Super Religare Laboratories Ltd.

• Biosyntech, Inc., Canada is acquired by Piramal. This is a part of the Life Science vertical, bio-orthopedics division.

2005

• Avecia Pharmaceutical is acquired.

• Forbes 2005 List of ‘Best Small Asian Companies’ ranks Piramal Healthcare as a high value achiever.

Piramal 2005
11
10
Piramal 2003

2003

• Global Bulk Drugs is acquired.

• Sarabhai Piramal is acquired.

2002

• ICI Pharma is acquired.

Piramal 2002
9
8
Piramal 2000

2000

• Started collaborative research with Centre for Biochemical Technology in the field of gene technology

1998

• Acquired the research unit of Hoechst Marion Roussel (India) in Mumbai.

Piramal 1998
7
6
Piramal 1996

1996

• Boehringer Mannheim is acquired.

1995

• Acquired the bulk drug division of Sumitra Pharmaceutical and Chemicals Ltd. Hyderabad.

Piramal 1995
5
4
Piramal 1993

1993

• Piramal entered into a joint venture agreement with Allergan, the leading manufactures of ophthalmic products

1992

• Nicholas Laboratories Ltd. renamed to Nicholas Piramal India, Ltd.

Piramal 1992
3
2
Piramal 1991

1991

• Formulation plant at Pithampur in Madhya Pradesh is commissioned and later expanded in 1992

1988

• Acquired Nicholas Laboratories, initiating entry into pharmaceuticals

Piramal 1988
1